Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo

Anticancer Research

Volumn 20, Issue 4, 2000, Pages 2723-2728

  Nagayama, Yuji ^a   Shigematsu, Kazuto ^a   Namba, Hiroyuki ^a   Zeki, Kazuya ^b   Yamashita, Shunichi ^a   Niwa, Masami ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Anaplastic thyroid carcinoma; Thrombospondin 1; Tumor suppressor gene; Vascular endothelial growth factor

Indexed keywords

PROTEIN P53; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CARCINOMA CELL; GENE THERAPY; GROWTH RATE; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; THYROID CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; DOGS; GENE THERAPY; GENES, P53; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; THROMBOSPONDIN 1; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033868115     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Braverman LE and Utiger RD: The Thyroid: a Fundamental and Clinical Text, 7th ed., pp 902-915, 1996, Lippincott-Raven, Philadelphia.
2. Braiden V, Nagayama Y, litaka M, Namba H, Niwa M and Yamashita S: Retrovirus-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter. Endocrinology 139: 3996-3999, 1993.
3. Nagayama Y, Nishihara E, Iitaka M, Namba H, Yamashita S and Niwa M: Enhanced therapeutic efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system. Cancer Res 59: 3049-3052, 1999.
4. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, Dohi K, Nakamura N and Akiyama M: Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid. Cancer Res 52: 1369-1371, 1992.
5. Donghi R, Longoni A, Pilotti S, Michieli P, Porta GD and Pierotti MA: Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91: 1753-1760, 1993.
6. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH and Koeffler HP: High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91: 179-184, 1993.
7. Gallagher WM and Brown R: p53-Oriented cancer therapies: current progress. Ann Oncol 10:139-150, 1999.
8. Soddu S and Sacchi A: p53: prospects for cancer gene therapy. Cytokine Cell Mol Ther 4: 177-185, 1993.
9. Yang T-T, Namba H, Hara T, Takamura N, Nagayama Y, Fukada S, Ishikawa N, Kuma K, Ito K and Yamashita S: p53 induced by ionizing radiation mediates DNA endjoining activity, but not apoptosis of thyroid cells. Oncogene 14: 1511-1519 1997.
10. Narimatsu M, Nagayama Y, Akino K, Yasuda M, Yamamoto T, Yang T-T, Ohtsuru A, Namba H, Yamashita S, Ayabe H and Niwa N: Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplasticthyroid carcinoma cell line. J Gin Endocrinol Metab 83: 3668-3672, 1998.
11. Kong H-L and Crystal RG: Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst 90: 273-286, 1998.
12. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
13. Oku T, Tjuvajev JG, Miyagawa T, Sasajima T, Joshi A, Joshi R, Finn R, Claffey KP and Blasberg RG: Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeabilitty, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res 55: 4185-4192, 1998.
14. Zeki K, Tanaka Y, Morimoto I, Nishimura Y, Kimura A, Yamashita U and Eto S: Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53. Int J Cancer 75: 391-395, 1998.
15. Sawano A, Takahashi T, Yamaguchi S, Aonuma M and Shibuya M: Flt-but not KCR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ 7: 213-221, 1996.
16. Tanaka T, Manome Y, Wen P, Kufe DW and Fine HA: Viral vectormediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nature Med 3: 437-442, 1997.
17. O'Reilly MS, Holmgren L, Chen C and Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 2: 689-692, 1996.
18. Holmgren L, O'Reilly MS and Folkman J: Dormancy of micro-metastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1: 149-153, 1995.
19. Roberts DD: Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 10: 1183-1191. 1996.